Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China's WuXi PharmaTech Leads $15 Million Investment in Claritas Genomics

publication date: Feb 2, 2015
WuXi NextCODE Genomics, the newly formed genomic analysis division of China CRO/CMO WuXi PharmaTech, led a $15 million Series B financing in Claritas Genomics. Claritas is a Boston-based lab that develops and provides next-gen sequence-based tests for pediatric genomic disorders. The company was spun out of Boston Children’s Hospital two years ago with assistance from Life Technologies. WuXi NextCODE was formed earlier this year when WuXi PharmaTech paid $65 million to acquire NextCODE Health, a genomics sequencing company. More details....

Stock Symbols: (NYSE: WX) (NSDQ: LIFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020